PeptideLabs Logo
PeptideLabs
All profiles

Bremelanotide

Peptide · Melanocortin

Influences central melanocortin signalling; approval covers only a specific prescription use.

Approved for specific uses
LibraryNo account · this device only

Also known as: PT-141 · Vyleesi

Use at a glance

Bremelanotide

Influences central melanocortin signalling; approval covers only a specific prescription use.

Medicine instructions · named product only

What amount?
1.75 mg
How often?
at most once per day · at most 8 times in 30 days
What time of day?
Time of day not stated here
In what setting?
event-based
How is it used?
The named medicines are ready-made injectable solutions. Their instructions and device are product-specific.
Does it need mixing?
No. The named ready-made solutions are not mixed with water. A research powder is a different product.
View preparationCheck sources
More factsPeptide · Melanocortin
Classification
Peptide · Melanocortin
Research focus
Influences central melanocortin signalling; approval covers only a specific prescription use.
Evidence
Established
Status
Approved for specific uses

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Schedule explained in detailApproved medicine

Amount status

VYLEESI label: 1.75 mg in 0.3 ml via a prefilled autoinjector for the narrowly defined approved HSDD population; not a general libido dose.

Profile evidence level: established.

Timing

At least 45 minutes before expected activity; no more than once within 24 hours.

No individual recommendation.

Cycle/duration

More than eight uses per month are not recommended in the label. Benefit and tolerability must be medically reassessed.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

No. The named ready-made solutions are not mixed with water. A research powder is a different product.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

10 mg · assumed final volume: 1 ml

Community calculation example
Calculated amount1.75 mg
Concentration10,000 µg/ml
U-10017.5 U
Volume0.175 ml

10 mg · assumed final volume: 2 ml

Community calculation example
Calculated amount1.75 mg
Concentration5,000 µg/ml
U-10035 U
Volume0.35 ml
All preparation informationProduct details and calculation examples from the available sources.

VYLEESI is supplied as a single-use prefilled autoinjector at 1.75 mg/0.3 ml. No reconstitution and no conversion from research vials.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Melanocortin receptor agonist

Bremelanotide is classified as “Melanocortin receptor agonist”. Influences central melanocortin signalling; approval covers only a specific prescription use. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Melanocortin receptor activation

This studies how activating melanocortin receptors affects pigmentation or sexual arousal signals, like a switch controlling different body functions depending on the receptor subtype. Skin pigmentation or physiological arousal markers are measured in studies.

02

Reproductive hormone signalling

This examines effects on hormone axes influencing libido, cycle, or fertility, similar to a feedback loop connecting several glands. Hormone levels and subjective questionnaires are measured in studies.

03

Neuroendocrine signalling

This examines how the nervous system and hormone-producing glands communicate with each other, similar to a two-way phone line connecting the brain to distant organs. Researchers typically measure hormone levels in blood alongside markers of nervous system activity.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Fertility and libido forums

Personal experiences with hormone-signalling peptides related to libido or cycle are discussed, often compared to approved products. Such experience reports are individual and do not replace medical evaluation or controlled studies.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

General wellness forums

Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.

Adverse effects and safety risks

  • Melanocortin activity can cause nausea, flushing, blood-pressure changes, headache, unwanted pigmentation and sexual adverse effects; non-selective analogues add uncertainty.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Atypical moles/skin-cancer risk, uncontrolled blood pressure, cardiovascular disease, priapism risk and pregnancy require medical assessment.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on the approved use, skin examination, blood pressure, nausea, pigment changes and indication-specific endpoints may be assessed.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Established

Approval applies only to the specifically studied use.

Clinical evidence

The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.

Bremelanotide is approved for a specific prescription use, unlike the unapproved Melanotan II.

Storage and stability

  • Per the label, store at up to 25 °C, do not freeze and protect from light.
  • Use only figures for the authentic finished product.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile